Simon Kerry

"SETsquared provided me with the tools and support that were needed to take Karus through the first part of its journey towards success."

Karus Therapeutics is developing innovative cancer medicines that directly target tumor growth and indirectly trigger an immunotherapeutic anti-tumor response.

Top 3 achievements:

• Taken two innovative drug programs from concept to clinic, with initial clinical studies being conducted at the University of Texas MD Anderson Centre, the world’s leading cancer research and care hospital.

• £30m investment to date, much of which has been made by leading healthcare investors based in the UK, US and Denmark (SV Life Sciences, New Leaf Venture Partners, Novo A/S, IP Group).

• Evolved from university spin-out to a fully-capable clinical-stage company, building a team of leaders and scientists that facilitated the company’s success.